Introduction
============

Hepatic stellate cells (HSCs) activation is responsible for liver fibrosis resulting from various chronic liver injury, as activated HSCs are implicated in the predominant source of extracellular matrix (ECM) accumulation. [@B1]. Physiologically, quiescent HSCs are required for retinoid homeostasis and ECM remodeling. Once activated, quiescent HSCs turn into myofibroblasts, accompanied with ECM overexpression [@B2]. However, no medicinal candidates specifically target HSCs, which limits the current antifibrotic therapy [@B3].

Oxidative stress is considered as a pivotal driver of liver fibrosis.[@B4]. Reactive oxygen species (ROS) accumulation promotes HSCs activation and transdifferentiation into myofibroblast, which are characterized by excessive ECM deposition, resulting in subsequent scar formation. Oxidative stress was detected both in human and mouse with liver fibrosis [@B5]. Furthermore, antioxidant treatment or antioxidant gene overexpression can prevent HSC activation in liver fibrosis [@B6], [@B7].

Oxidative stress is associated with numerous downstream molecules that contribute to liver fibrosis. In light of the recent study, NOD-like receptor protein 3 (NLRP3) inflammasome, is identified as a novel contributor of liver fibrosis [@B8]. NLRP3 inflammasome activation triggers the release of interleukin (IL)-1β and IL-18, contributing to HSC activation [@B9], [@B10]. Although intracellular ROS provokes NLRP3 inflammasome activation [@B11]-[@B13], the source and regulation of ROS remain to be clarified.

The mitochondrial ROS accounts for the majority of intracellular ROS [@B14]. The 66 kDa isoform of Shc (p66Shc), is vital for mitochondria-dependent oxidative balance [@B15]. Under cellular stress conditions, p66Shc catalyzes electron transfer from Cytochrome c to oxygen, which gives rise to the enhancement of hydrogen peroxide (H~2~O~2~) [@B16]. In response to obesity, ischemic myocardial injury, and Alzheimer\'s disease, circulating and tissue ROS levels and ROS-mediated damage are decreased in p66Shc knockout mice [@B17]-[@B19]. More recently, we identified p66Shc as a crucial mediator of hepatocyte oxidative stress. The protective effects of p66Shc downregulation partly attributes to a reduction of cellular ROS in hepatocytes [@B20]-[@B22]. However, the potential role of p66Shc in liver fibrosis needs to be further clarified. Additionally, increased expression of p66Shc mRNA in humans is significantly correlated with the degree of liver fibrosis [@B23], suggesting that p66Shc may contribute to liver fibrosis.

In this study, we explored whether p66Shc is involved in liver fibrosis. First, p66Shc expression in human and mouse fibrotic liver tissues was detected. Second, p66Shc knockdown was performed both *in vivo* and *in vitro*. Third, we elucidated the underlying mechanisms by which p66Shc participates in liver fibrosis through NLRP3 inflammasome activation.

Methods
=======

Mice and liver injury
---------------------

C57BL/6 mice (male) were injected with lentivirus-p66Shc-shRNA or lentivirus-scramble (1× 10^9^ viral particles/mouse) via the tail vein. After 7 days, carbon tetrachloride (CCl~4~) was employed by intraperitoneal injections eight times during four weeks. Each injection contained a CCl~4~ dose of 1, 2, and 4 ml/kg diluted in corn oil. Mice were euthanized 48 h after the last injection. Animal experiments were applied according to the Guidelines for the Care and Use of Laboratory Animals, and were approved by the Institutional Ethics Committee of Dalian Medical University (Dalian, China).

Human liver samples
-------------------

Twelve normal and twelve liver fibrosis tissue samples were obtained from the Second Affiliated Hospital of Dalian Medical University (Dalian, China). The informed consent was signed by all patients. Liver samples were handled by the approval of the Ethics Committee of Dalian Medical University.

Histologic examination and immunohistochemical staining
-------------------------------------------------------

Liver tissue sections were collected and fixed in 4% paraformaldehyde at room temperature at least overnight, and were applied to Hematoxylin-eosin (H&E) and Masson staining. Fibrosis stage was assessed according to the Ishak score [@B24].

Immunohistochemistry (IHC) of α-SMA, or p66Shc was performed on paraffin sections (4 μm). Section were incubated with p66Shc or α-SMA (Proteintech) antibody overnight, and were visualized with DAB and hematoxylin. The number of positive cells was quantified with ImageJ software.

Biochemical assays
------------------

Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were assessed with assay kits, respectively (Jiancheng Corp., Nanjing, China).

Hydrogen peroxide (H~2~O~2~) content and superoxide dismutase (SOD) activity were assessed with assay kits (Jiancheng Corp.).

HSC isolation and culture
-------------------------

Primary rat HSCs were isolated with proteinase/ collagenase digestive enzymes as previously described [@B25], and were maintained in DMEM (Gibco, Carlsbad, CA, USA) at 37 ℃ with 5% CO~2~.

Cell transfection
-----------------

Primary HSCs were transfected with small interfering RNA (siRNA), pcDNA plasmid or negative control (GenePharma, Suzhou, China) for 48 h using Lipofectamine 3000 (Invitrogen, Carlsbad, CA, USA). The p66Shc siRNA sequence was sense 5\'-GCA ACU UGA AGC UGG CCA ATT-3\', antisense 5\'-UUG GCC AGC UUC AAG UUG CTT-3\'. The NLRP3 siRNA sequence was sense: 5\'-GAU CCU AUU UGA AGA GUG U-3\', antisense 5\'-GAU CAA CCU CUC UAC CAG A-3\'. Then cells were incubated with transforming growth factor-β1 (TGF-β1, 2 ng/ml for 24 h, Promega, USA) for different assays.

Western blotting
----------------

Proteins were separated via SDS-PAGE (10-12%). The relevant primary antibodies that were specific for p66Shc (BD Biosciences, USA); cleaved caspase-1 (Affinity Biosciences, USA); Col1a1 (Abcam Ltd., Cambridge, UK);IL-18 (ABclonal Biotechnology, Wuhan, China); α-SMA, NLRP3, adaptor apoptosis- associated speck-like protein (ASC), superoxide dismutase 2 (SOD2), mitochondrial uncoupling protein 1 (UCP1), IL-1β, Cytochrome *c*, β-actin and voltage-dependent ion channel (VDAC, Proteintech Group, Wuhan, China), followed by secondary antibodies incubation.

RNA isolation and quantificational reverse transcription-polymerase chain reaction (qRT-PCR)
--------------------------------------------------------------------------------------------

TRIzol (Invitrogen) was applied for total RNA extraction. Then cDNA synthesis and RNA abundance were performed with primeScript^TM^ RT reagent kit and SYBR Premix Ex Taq^TM^ II (TaKaRa, Japan), respectively. Expression levels normalized to β-actin levels in each sample were determined by calculating ΔΔCt. The primer sequences were shown in Table [1](#T1){ref-type="table"}.

Dual immunofluorescence microscopy
----------------------------------

After fixed in 4% paraformaldehyde, The cells and liver tissue sections were incubated with primary antibody at 4 ℃ overnight followed by secondary antibody incubation (Proteintech) at 37 ℃ for 1 h. Subsequently, DAPI (Beyotime Institute of Biotechnology, Hangzhou, China) was used for nuclear staining. Immunofluorescence images were collected under 80i Nikon confocal microscope.

Mitochondrial ROS level determination
-------------------------------------

Mitochondrial ROS level was determined by visualization with MitoSOX Red (Invitrogen) or MitoTracker Red CMXRos (Invitrogen). Briefly, primary rat HSCs were plated on coverslips and incubated with 5 μM MitoSOX Red or 200 nM MitoTracker at 37 ℃ for 10 min. The nuclei were identified by Hoechst 33342 staining (Beyotime Institute of Biotechnology) in the dark for 5 min. Immunofluorescence images were collected under 80i Nikon confocal microscope.

Cells were stimulated with 150 μg/ml monosodium urate (MSU), and mitochondrial respiratory complex inhibiter (10 μM rotenone; 10 μM thenoyltrifluoroacetone, TTFA; 40 μg/ml antimycin A) for 6 h, or 100 μM mito-TEMPO for 3 h. MSU, a well-known NLRP3 inflammasome activator, was used to experimentally induce inflammasome activation. The reagents above were from Sigma (Missouri, USA).

Mitochondrial membrane potential
--------------------------------

JC-1 probe (Beyotime Institute of Biotechnology) was carried out for mitochondrial membrane potential detection. Cells were loaded with JC-1 probe according to the instruction. Then, nuclei were detected by DAPI staining (Beyotime Institute of Biotechnology) in the dark. The red and green JC-1 fluorescence ratio was calculated.

Transmission electron microscopy (TEM)
--------------------------------------

TEM was performed to observe the mitochondrial morphology. Primary HSCs were fixed and embedded. Then ultrathin sections (50 μm thick) were prepared. The sections were dehydrated in a gradient of ethanol, and embedded in epoxy resin. Lead citrate and uranyl acetate were used for staining. The images were obtained using a transmission electron microscope (JEOL, Peabody, MA).

Mitochondria isolation
----------------------

Mammalian mitochondrial isolation kit (BioVision, Milpitas, CA, USA) was performed for mitochondria isolation. The samples were homogenized in Mitochondrial Isolation Buffer using a precooled glass homogenizer. The samples were stored on ice and then centrifuged at 4 ℃. The mitochondria were resuspended in Storage Buffer.

Intracellular adenosine triphosphate (ATP) level assay
------------------------------------------------------

Intracellular ATP levels were measured with assay kit in accordance with the assay instructions (Beyotime Institute of Biotechnology).

Statistical analysis
--------------------

Student\'s unpaired *t* test (two-group comparisons) and one-way ANOVA test (multi-group comparisons) were performed using GraphPad Prism. Data are expressed as the means±standard deviation (SD). *P*\<0.05 was taken significant.

Results
=======

p66Shc expression is correlated with liver fibrosis in mice
-----------------------------------------------------------

Western blotting and qRT-PCR analyses indicated that p66Shc, Col1a1 and α-SMA expression were strongly increased in fibrotic samples induced by CCl~4~ in comparison to the control (Figure [1](#F1){ref-type="fig"}A-B). H&E staining, Masson staining and IHC for α-SMA exhibited mild to severe fibrosis with different dosages of CCl~4~ treatment. As shown in Figure [1](#F1){ref-type="fig"}C-D, IHC analyses revealed that there was a positive correlation between the increased p66Shc expression and liver fibrosis progression. Notably, the p66Shc expression pattern coincided with that of α-SMA and Col1a1 expression in the fibrotic livers (Figure [1](#F1){ref-type="fig"}C), indicating enhanced p66Shc expression in activated HSCs. In addition, p66Shc mRNA was increased in the fibrotic livers, correlating with HSC activation, as observed by the induction of α-SMA mRNA (Figure [1](#F1){ref-type="fig"}E). Taken together, p66Shc expression is positively correlated with liver fibrosis progression.

p66Shc silencing attenuates liver fibrosis in mice
--------------------------------------------------

Then, we focused on the contribution of p66Shc to liver fibrosis. p66Shc silencing via lentiviral transduction was delivered into mice. Western blotting and qRT-PCR were carried out to assess the efficiency of p66Shc knockdown *in vivo*. As shown in Figure [2](#F2){ref-type="fig"}A-B, p66Shc expression was inhibited (approximately 70\~80% reduction) by p66Shc silencing. As expected, p66Shc silencing markedly recovered SOD2 and UCP1 protein, SOD activity, as well as decreased H~2~O~2~ content and Cytochrome *c* release, indicating that intracellular ROS may contribute to the mechanism of p66Shc in liver fibrosis. Moreover, α-SMA and Col1a1, the most abundant ECM protein in the fibrotic livers, were notably abolished by concomitant p66Shc silencing (Figure [2](#F2){ref-type="fig"}B-E). Consistently, Masson staining assays revealed that p66Shc knockdown inhibited collagen accumulation (Figure [2](#F2){ref-type="fig"}F-G). p66Shc silencing also alleviated histological liver damage, evidenced by H&E staining (Figure [2](#F2){ref-type="fig"}F), and decreased serum ALT and AST concentrations (Figure [2](#F2){ref-type="fig"}H). The results demonstrated that p66Shc knockdown attenuates liver injury and decelerates liver fibrosis *in vivo*.

Since the NLRP3 inflammasome acts as a novel regulator of HSCs activation and ECM production, the contribution of p66Shc to NLRP3 inflammasome activation was determined. NLRP3 inflammasome complex (NLRP3, ASC, cleaved caspase-1, IL-1β and IL-18) protein were increased in CCl~4~-treated mice, and this increase was blocked by p66Shc silencing (Figure [2](#F2){ref-type="fig"}I). Furthermore, p66Shc knockdown significantly attenuated HSC activation, indicated by the decrease in CTGF and TIMP1 mRNA levels (Figure [2](#F2){ref-type="fig"}J). Taken together, these results suggest that p66Shc silencing inhibits HSC activation, which may be related to NLRP3 inflammasome activation.

p66Shc contributes to HSC activation *in vitro*
-----------------------------------------------

Activated HSCs are responsible for ECM production and liver fibrosis [@B26], and TGF‐β1 is implicated as a key driver of HSC activation [@B27]. To assess whether p66Shc is involved in HSCs activation *in vitro*, primary HSCs were transfected with p66Shc siRNA (Figure [3](#F3){ref-type="fig"}A-C) or pcDNA-p66Shc (Figure [3](#F3){ref-type="fig"}D-E) following TGF-β1 challenge. We found that p66Shc knockdown by siRNA significantly blunted the Col1a1 and α-SMA protein, as well as CTGF and TIMP1 mRNA, two specific markers of HSC activation (Figure [3](#F3){ref-type="fig"}A-B). Double immunofluorescence staining showed that p66Shc localized with α-SMA- positive cells, and the increase in p66Shc and α-SMA induced by TGF-β1 was eliminated by transfection with p66Shc siRNA. Additionally, during the process of activation, primary HSCs acquired contractile and fibrogenic myofibroblast-like phenotype and enhanced HSC activation markers (α-SMA, CTGF and TIMP1), which was reversed by p66Shc siRNA (Figure [3](#F3){ref-type="fig"}C). In contrast, p66Shc overexpression amplified HSCs activation induced by TGF-β1 (Figure [3](#F3){ref-type="fig"}D-E). These results indicate that p66Shc contributes to HSC activation *in vitro*.

p66Shc promotes HSC activation via NLRP3 inflammasome activation
----------------------------------------------------------------

To study the underlying mechanism of p66Shc on liver fibrosis, primary HSCs were transfected with p66Shc siRNA (Figure [4](#F4){ref-type="fig"}A-D) or pcDNA vector (Figure [4](#F4){ref-type="fig"}E). During chronic liver injury, inflammation provokes HSC activation and NLRP3 inflammasome is associated with primary mouse HSCs or LX-2 HSCs activation [@B9], [@B28]. As shown in Figure [4](#F4){ref-type="fig"}A-B, both p66Shc (green) and NLRP3 (green) colocalized with mitochondria that were stained with MitoTracker (red). Furthermore, double immunofluorescence staining showed that p66Shc (red) and NLRP3 (green) were colocated in HSCs (Figure [4](#F4){ref-type="fig"}C). Therefore, p66Shc and NLRP3 were closely associated in mitochondria. Consistent with the results *in vivo*, p66Shc knockdown significantly impaired NLRP3 inflammasome activation in HSCs exposed to TGF-β1 stimulation, while p66Shc overexpression enhanced NLRP3 inflammasome activation (Figure [4](#F4){ref-type="fig"}D-E). Thus, p66Shc contributes to HSC activation through NLRP3 inflammasome activation.

p66Shc triggers NLRP3 inflammasome activation through the regulation of mitochondrial ROS
-----------------------------------------------------------------------------------------

Mitochondrial ROS exerts a crucial role on NLRP3 inflammasome activation [@B29]. Then, we analyzed whether p66Shc-mediated mitochondrial ROS is involved in NLRP3 inflammasome activation. In primary HSCs, p66Shc knockdown triggered a notable increase in SOD2 and UCP1 protein, SOD activity and ATP content, as well as a dramatic decrease in H~2~O~2~ and Cytochrome *c* release to ameliorate oxidative stress in response to TGF-β1 (Figure [5](#F5){ref-type="fig"}A-E). Additionally, mitochondrial ROS was assessed by mitoSOX that served as a mitochondrial superoxide indicator. As shown in Figure [5](#F5){ref-type="fig"}F, mitochondrial ROS production was enhanced after exposure to TGF-β1 and was successfully reduced by p66Shc siRNA. Furthermore, the role of p66Shc in mitochondrial function was also characterized. The dysfunction of mitochondrial membrane potential was induced by TGF-β1 treatment, indicated by JC-1 monomers with green in the cytoplasm; however, p66Shc knockdown improved the normalization of mitochondrial membrane potential, shown by enhanced JC-1 monomers with red in the mitochondria (Figure [5](#F5){ref-type="fig"}G). In addition, p66Shc siRNA also substantially rescued the swollen mitochondria with disorganized and fragmented cristae induced by TGF-β1 (Figure [5](#F5){ref-type="fig"}H). As shown in Figure [S1](#SM0){ref-type="supplementary-material"}, p66Shc siRNA improved oxygen consumption rate (OCR) in response to TGF-β1. Collectively, these findings indicate that p66Shc knockdown attenuates mitochondrial ROS production and mitochondrial dysfunction in HSCs.

Next, we focused on the association between mitochondrial ROS and NLRP3 inflammasome activation in primary HSCs. Mitochondrial electron transport is the principal intracellular producer of ROS. Rather than complex II, respiratory complexes I and III are generally considered the main ROS producers in mitochondria [@B14]. Consistently, NLRP3 and IL-1β expression were increased as a result of mitochondrial ROS overproduction induced by rotenone (complex I inhibitor) and antimycin A (complex III inhibitor), respectively. Meanwhile, little or no effect was observed with the complex II inhibitor TTFA (Figure [6](#F6){ref-type="fig"}A). These data provide the evidence that mitochondrial ROS can trigger NLRP3 inflammasome activation. Furthermore, p66Shc overexpression amplified NLRP3 inflammasome activation in the presence of rotenone and antimycin A (Figure [6](#F6){ref-type="fig"}B). To further examine the effect of mitochondrial ROS production mediated by p66Shc on NLRP3 activation, primary HSCs were transfected with pcDNA-p66Shc in the absence or presence of mito-TEMPO, a specific mitochondrial ROS scavenger. Under TGF-β1 stimulation, p66Shc overexpression resulted in robust ROS production, which was blocked by mito-TEMPO, as detected by Mito-SOX (Figure [6](#F6){ref-type="fig"}C). Consequently, the high levels of NLRP3 and IL-1β induced by p66Shc overexpression were significantly abrogated by mito-TEMPO (Figure [6](#F6){ref-type="fig"}D). As expected, the reduction in mitochondrial ROS induced by mito-TEMPO substantially attenuated liver fibrosis (Col1a1 and α-SMA) as well as HSC activation (CTGF and TIMP1) in the presence of p66Shc overexpression (Figure [6](#F6){ref-type="fig"}D-E). Similar results were obtained with LX-2 cells. Moreover, p66Shc overexpression elevated the expression of Col1a1, α-SMA, CTGF and TIMP1, which was attenuated by NLRP3 siRNA (Figure [6](#F6){ref-type="fig"}F-G). Considering all the above findings, these data suggest that the underlying mechanism of the effect of p66Shc on NLRP3 activation in liver fibrosis is likely mediated through mitochondrial ROS.

p66Shc upregulation and NLRP3 inflammasome activation are involved in human liver fibrosis
------------------------------------------------------------------------------------------

To dissect the biological relevance of p66Shc during liver fibrosis in clinical situations, the expression of p66Shc was compared between healthy control and fibrosis patients. Consistently, p66Shc mRNA and protein were elevated significantly, and dysregulation of antioxidant responses were detected as evidenced by decreased SOD2 and UCP1 levels. Moreover, the accumulation of collagen and α-SMA were observed in fibrotic livers (Figure [7](#F7){ref-type="fig"}A-B). Intriguingly, the NLRP3 inflammasome was activated (Figure [7](#F7){ref-type="fig"}C). Furthermore, CTGF and TIMP1 mRNA levels were dramatically higher in fibrotic livers than in healthy control livers (Figure [7](#F7){ref-type="fig"}D). Taken together, p66Shc upregulation and NLRP3 inflammasome activation are involved in human liver fibrosis.

Discussion
==========

Our study firstly addressed the crucial role of p66Shc in liver fibrosis. First, p66Shc expression was significantly elevated in patients with fibrosis and in murine fibrotic models, and positively correlated with liver fibrosis stage in mice. Second, p66Shc silencing alleviated liver fibrosis *in vivo*. Third, p66Shc functioned as a contributor of HSC activation by activating the NLRP3 inflammasome. Therefore, p66Shc is a novel regulator of HSC activation and therapeutic target in liver fibrosis.

HSC activation represents the dominant event in liver fibrosis [@B26]. When exposed to pathophysiological cues, HSCs become activated and adopt a myofibroblast-like phenotype. These cells have been identified as the main producers of collagens and other ECM components, making them as the main concern for antifibrotic therapies [@B3]. In this study, enhanced p66Shc expression was related to liver fibrosis, especially in fibrotic patients. In addition, p66Shc expression was enhanced in activated HSCs (α-SMA-positive HSCs) and correlated with fibrosis progression. More importantly, p66Shc silencing blocked HSC activation induced by CCl~4~ administration. *In vitro*, we further found that p66Shc expression was remarkably elevated by TGF-β1 in primary HSCs. Knockdown of p66Shc apparently abolished the increase of CTGF and TIMP1 levels, two markers of HSC activation, whereas p66Shc overexpression exacerbated CTGF and TIMP1 abundance in response to TGF-β1 stimulation in primary HSCs. Additionally, we found that TGF-β1-induced primary HSCs was less responsive to apoptosis after inhibition and overexpression of p66Shc (data not shown). Therefore, p66Shc is an important mediator of HSC activation in liver fibrosis.

Although, liver fibrosis has much in common with fibrosis in other organs, such as the lungs and kidneys [@B2], our findings are not applicable to all fibrosis processes. In renal fibrosis, p66Shc overexpression occurs paralleled with mitochondrial ROS overproduction and the fibrosis process [@B30]. However, p66Shc knockout *ob/ob* mice exhibited higher subcutaneous adipose tissue (SAT) collagen production and no protection against visceral adipose tissue (VAT) fibrosis [@B18]. Additionally, p66Shc knockout mice exhibit interstitial and alveolar fibrosis after cigarette smoke exposure [@B31]. Unlike in HSCs, the prohibitive apoptosis by p66Shc silencing interferes with the macrophage "clearance" from alveolar spaces and increases M2 cytokines and enzymes levels in macrophages, which can promote TGF-β expression, collagen deposition, and fibrosis in the surrounding areas. The different effects of p66Shc activation and silencing in different cells, tissues and organs may result from tissue specificity and the different mechanisms underlying fibrosis progression [@B26], [@B32].

Adaptor protein p66Shc is an attractive isoform of ShcA due to its additional CH2 domain, which is responsible for its redox property [@B16]. p66Shc is expressed in many tissues, where it contributes to organ dysfunction by promoting mitochondrial ROS production [@B33]. p66Shc^-/-^ mice exhibit decreased intracellular ROS levels, and display increased resistance to oxidative stress [@B34]. Mitochondrial ROS represents the majority of intracellular ROS, particularly in persistent dysfunction including liver fibrosis [@B35]. p66Shc is identified as a central molecular of the mitochondrial oxidative stress [@B15]. p66Shc is partially located in mitochondria, where it promotes Cytochrome *c* release and functions as an oxidoreductase, resulting in H~2~O~2~ formation, the main ROS production [@B16]. In this study, we found that p66Shc silencing attenuated CCl~4~/TGF-β1-induced ECM and mitochondrial ROS accumulation both *in vivo* and *in vitro*. Mitochondria-localized p66Shc was involved in mitochondrial membrane potential, mitochondrial morphology and cellular metabolism by mitochondrial ROS accumulation. Additionally, in primary HSCs, we found that the release of Cytochrome *c* induced by TGF-β1 was restrained by p66Shc knockdown, along with a reduction in H~2~O~2~ content. Similar results were obtained *in vivo*. These findings indicated that p66Shc contributes to liver fibrosis via mitochondrial ROS.

NLRP3 inflammasome activation is a novel contributor in liver fibrosis [@B9]. Mitochondrial ROS plays a crucial role in NLRP3 inflammasome activation. Evidence is emerging to support that ROS generated by the mitochondrial respiratory chain exerts a pivotal effect on NLRP3 inflammasome activation [@B29]. Robust mitochondrial ROS production was driven by mitochondrial complex I inhibitor rotenone and complex III inhibitor antimycin A [@B36]. In primary HSCs, we found that rotenone and antimycin A stimulation caused NLRP3 inflammasome activation, and furthermore, mitochondrial ROS production regulated by p66Shc was involved in NLRP3 inflammasome activation. Confocal laser scanning microscopy showed that NLRP3 and p66Shc colocalized with mitochondria in HSCs. Importantly, knockdown of p66Shc significantly impaired NLRP3 inflammasome activation, while p66Shc overexpression abolished the results described above. In addition, treatment of primary HSCs and LX-2 cells with mito-TEMPO, a specific mitochondrial ROS scavenger, abrogated mitochondrial ROS release and blocked the NLRP3 inflammasome activation induced by p66Shc overexpression. As a result, mito-TEMPO suppressed the increase in Col1a1 and α-SMA enhanced by p66Shc overexpression in activated HSCs. Moreover, the mitochondrial ROS production blocked by p66Shc silencing attenuated liver fibrosis, based on Masson staining and Col1a1 expression *in vivo*. Thus, p66Shc-triggered NLRP3 inflammasome activation is mainly dependent on mitochondrial ROS, which promotes HSC activation and liver fibrosis.

Accumulating evidence reveals that ROS is crucial for HSC activation in liver fibrosis. In light of the important role played by ROS in liver fibrosis, strategies aimed at blocking ROS production are currently being researched [@B37]. Indeed, antioxidants were found to be beneficial against liver fibrosis in mice [@B38]. Nevertheless, the clinical benefits of antioxidant agents are not promising [@B39]. The main factor considered to account for this failure is that exogenous antioxidant agents may function differently from endogenous agents [@B40]. p66Shc is crucially involved in the intracellular redox balance and oxidative stress levels. The reported protection achieved by p66Shc deletion is primarily due to the reduction in intracellular free radicals [@B17], [@B19], [@B41]. In this study, our data suggest that p66Shc silencing protected mice from liver fibrosis by blunting the production of free radicals and that the ROS mediator p66Shc is a crucial trigger for liver fibrosis. Therefore, the development of treatment strategies controlling p66Shc function may represent a more effective alternative to combat liver fibrosis, and may be developed into more specific and powerful drugs against liver fibrosis. Furthermore, analysis of a large set of clinical samples is required to validate the clinical correlation between p66Shc expression and the stage of liver fibrosis.

Collectively, for the first time, our study demonstrated that p66Shc is essential for HSC activation and liver fibrosis through NLRP3 inflammasome activation. These findings identify p66Shc as a critical regulator of liver fibrosis and provide mechanistic insights into liver fibrosis progression that can be exploited for pharmacological intervention.
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![**p66Shc expression is correlated with liver fibrosis in mice.** (A) p66Shc, Col1a1, α-SMA protein levels, n=3. (B) p66Shc, Col1a1, α-SMA mRNA levels, n=6. (C) H&E staining, Masson staining, IHC staining for α-SMA and p66Shc, and dual immunofluorescence staining for p66Shc and α-SMA, as well as for p66Shc and Col1a1. Scale bar, 200 μm. (D) Pearson\'s correlation analyses of p66Shc IHC scores with Ishak scores of Masson staining (r=0.798, P\<0.01). (E) Pearson\'s correlation analyses of p66Shc mRNA with α-SMA mRNA (r=0.696, P\<0.05). ^\#\#^P\<0.01.](thnov09p1510g001){#F1}

![**p66Shc silencing attenuates liver fibrosis in mice.** p66Shc silencing was induced via lentivirus delivered to C57BL/6 mice exposed to CCl~4~ (2 ml/kg). (A) Liver p66Shc mRNA expression, n=6. (B) Liver p66Shc, SOD2, UCP1, Col1a1, α-SMA protein, n=3. (C) H~2~O~2~ content, n=8. (D) SOD activity, n=8. (E) Cytochrome *c* expression in the cytoplasm and mitochondria, n=3. (F) H&E and Masson staining. Scale bar, 200 μm. (G) Ishak score of Masson staining. (H) Serum ALT and AST levels, n=8. (I) Liver NLRP3 inflammasome protein expression, n=3. (J) Liver CTGF and TIMP1 mRNA levels, n=6. ^\#\#^P\<0.01, ^\#^P\<0.05.](thnov09p1510g002){#F2}

![**p66Shc contributes to HSC activation *in vitro*.** Primary HSCs were transfected with p66Shc siRNA (A-C) or pcDNA-p66Shc (D, E) and then exposed to TGF-β1. (A) p66Shc, Col1a1, α-SMA protein, n=3. (B) CTGF and TIMP1 mRNA, n=6. (C) Dual immunofluorescence of p66Shc and α-SMA. Representative immunofluorescence images in the left panel. Scale bar, 200 μm. Representative cell area in the right panel. (D) p66Shc, Col1a1, α-SMA protein expression, n=3. (E) CTGF and TIMP1 mRNA expression, n=6. ^\#\#^P\<0.01.](thnov09p1510g003){#F3}

![**p66Shc is essential for HSC activation via NLRP3 inflammasome activation.** Primary HSCs were transfected with p66Shc siRNA (A-D) or pcDNA-p66Shc vector (E) and further exposed to TGF-β1. (A, B) The colocalization of p66Shc and mitochondria (MitoTracker), as well as NLRP3 and mitochondria (MitoTracker). Scale bar, 12.5 μm. (C) Dual immunofluorescence of p66Shc and NLRP3. Scale bar, 12.5 μm. (D, E) NLRP3 inflammasome protein expression, n=3. ^\#\#^P\<0.01, ^\#^P\<0.05.](thnov09p1510g004){#F4}

![**p66Shc knockdown attenuates mitochondrial ROS production and mitochondrial dysfunction in primary HSCs.** p66Shc knockdown was carried out by p66Shc siRNA in the presence of TGF-β1. (A) SOD2 and UCP1 protein levels, n=3. (B) H~2~O~2~ content, n=8. (C) SOD activity, n=8. (D) Cytochrome *c* expression in the cytoplasm and mitochondria; n=3. (E) ATP content, n=8. Representative fluorescence images of MitoSOX (F)- and JC-1 (G)-stained cells. Scale bar, 200 μm. (H) Mitochondrial morphology was determined via TEM (1500×, magnification, red arrow). ^\#\#^P\<0.01, ^\#^P\<0.05.](thnov09p1510g005){#F5}

![**p66Shc triggers NLRP3 inflammasome activation through regulation of mitochondrial ROS production.** (A) Primary HSCs were stimulated with MSU and mitochondrial complex inhibitor (rotenone, TTFA and antimycin A). NLRP3 and IL-1β protein expression, n=3. (B) p66Shc overexpression was carried out in primary HSCs by pcDNA-p66Shc vector and then rotenone or antimycin A was stimulated. NLRP3 and IL-1β protein expression, n=3. (C-E) p66Shc overexpression was applied in primary HSCs by pcDNA-p66Shc vector transfection and then mito-TEMPO was stimulated under TGF-β1 treatment. (C) Representative fluorescence images of MitoSOX. (D) NLRP3, IL-1β, Col1a1, α-SMA protein levels, n=3. (E) CTGF and TIMP1 mRNA expression, n=6. (F-G) Primary HSCs were co-transfected with pcDNA-p66Shc and NLRP3 siRNA following TGF-β1 challenge. (F) NLRP3, IL-1β, Col1a1, α-SMA protein levels, n=3. (G) CTGF and TIMP1 mRNA expression, n=6. ^\#\#^P\<0.01, ^\#^P\<0.05.](thnov09p1510g006){#F6}

![**p66Shc upregulation and NLRP3 inflammasome activation are involved in human liver fibrosis.** Relative protein expression and mRNA were measured in patients with liver fibrosis. (A) p66Shc mRNA levels. (B) p66Shc, SOD2, UCP1, Col1a1, α-SMA protein levels. (C) NLRP3 inflammasome protein levels. (D) CTGF and TIMP1 mRNA levels. n=12. ^\#\#^P\<0.01, ^\#^P\<0.05.](thnov09p1510g007){#F7}

###### 

Primer sequences

  Gene            Forward primer            Reverse primer
  --------------- ------------------------- -------------------------
  p66Shc mouse    GTCCGACTACCTGTGTTCCTT     CAGCAGGATTGGCCAGCTT
  Col1a1 mouse    TGACTGGAAGAGCGGAGAGATCT   TTCGGGCTGATGTACCAGTTC
  α-SMA mouse     TGCCGAGCGTGAGATTGTC       CGTTCGTTTCCAATGGTGATC
  β-actin mouse   AGAGGGAAATCGTGCGTGAC      CAATAGTGATGACCTGGCCGT
  CTGF rat        GCCTACCGACTGGAAGACACA     CAGCCTGCAGAAGGTATTGTCA
  TIMP1 rat       TGGTTCCCTGGCATAATCTGA     GGATCTGATCTGTCCACAAGCA
  β-actin rat     GGAAATCGTGCGTGACATTAAAG   CGGCAGTGGCCATCTCTT
  p66Shc human    GAGGCCATCAGTCTGGTGTGT     GCTGGTGGAGACGGTGAGA
  β-actin human   ACCCTGAAGTACCCCATCGAG     ACATGATCTGGGTCATCTTCTCG
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